within Pharmacolibrary.Drugs.ATC.L;

model L01FF05
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.3333333333333333e-06,
    adminDuration  = 600,
    adminMass      = 1200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00691,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00368,
    k12             = 0.278,
    k21             = 0.278
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01FF05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Atezolizumab is a humanized monoclonal antibody of the IgG1 isotype that selectively binds to programmed death-ligand 1 (PD-L1). It is used in cancer immunotherapy for several malignancies including non-small cell lung cancer (NSCLC), urothelial carcinoma, triple-negative breast cancer, and more. It is FDA- and EMA-approved for several cancer indications and continues to be used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic analysis in cancer patients (adults) across clinical trials (n > 800), both sexes, mostly with advanced solid tumors (including NSCLC, urothelial carcinoma).</p><h4>References</h4><ol><li><p>Burotto, M, et al., &amp; Felip, E (2023). IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications. <i>Annals of oncology : official journal of the European Society for Medical Oncology</i> 34(8) 693–702. DOI:<a href=\"https://doi.org/10.1016/j.annonc.2023.05.009\">10.1016/j.annonc.2023.05.009</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37268157/\">https://pubmed.ncbi.nlm.nih.gov/37268157</a></p></li><li><p>Burotto, M, et al., &amp; Felip, E (2024). Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC. <i>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</i> 19(10) 1460–1466. DOI:<a href=\"https://doi.org/10.1016/j.jtho.2024.05.005\">10.1016/j.jtho.2024.05.005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38729426/\">https://pubmed.ncbi.nlm.nih.gov/38729426</a></p></li><li><p>Felip, E, et al., &amp; Restuccia, E (2021). Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer. <i>Clinical pharmacology in drug development</i> 10(10) 1142–1155. DOI:<a href=\"https://doi.org/10.1002/cpdd.936\">10.1002/cpdd.936</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33788415/\">https://pubmed.ncbi.nlm.nih.gov/33788415</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01FF05;
